Literature DB >> 28115350

Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.

Ray Hachem1, Ruth Reitzel2, Kenneth Rolston2, Anne-Marie Chaftari2, Issam Raad2.   

Abstract

A total of 521 unique clinical isolates from cancer patients with primarily (>90%) bloodstream infections were tested for susceptibility to ceftazidime-avibactam and comparators using broth microdilution methods. Ceftazidime-avibactam inhibited 97.8% of all Enterobacteriaceae (n = 321) at the susceptibility breakpoint of ≤8/4 μg/ml (there were 7 nonsusceptible strains). It was also active against Pseudomonas aeruginosa (91.7% isolates susceptible, n = 121), including many isolates not susceptible to meropenem, cefepime, ceftazidime, piperacillin-tazobactam, or other comparators.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  avibactam; cancer patients; ceftazidime; clinical isolates

Mesh：

Substances：

Year:  2017        PMID： 28115350      PMCID： PMC5365661          DOI： 10.1128/AAC.02106-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.

Authors:  Marco Falcone; David Paterson
Journal:  J Antimicrob Chemother       Date:  2016-07-17       Impact factor: 5.790

2.  The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013.

Authors:  Bernardo Rapoport; Jean Klastersky; Harry Raftopoulos; Allison Freifeld; Mickael Aoun; Stephen H Zinner; Kenneth V I Rolston
Journal:  Support Care Cancer       Date:  2016-04-20       Impact factor: 3.603

3.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 4.  Antibiotic-resistant gram-negative bacterial infections in patients with cancer.

Authors:  Federico Perez; Javier Adachi; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

5.  Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.

Authors:  Nizar Andria; Oryan Henig; Offer Kotler; Alexander Domchenko; Ilana Oren; Tsila Zuckerman; Yishai Ofran; Drora Fraser; Mical Paul
Journal:  J Antimicrob Chemother       Date:  2015-07-24       Impact factor: 5.790

6.  Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line-Associated Bloodstream Infections From Oncology Settings, 2009-2012.

Authors:  Isaac See; Alison G Freifeld; Shelley S Magill
Journal:  Clin Infect Dis       Date:  2016-03-01       Impact factor: 9.079

Review 7.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24

8.  Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.

Authors:  M Ortega; F Marco; A Soriano; M Almela; J A Martínez; A Muñoz; J Mensa
Journal:  J Antimicrob Chemother       Date:  2009-01-06       Impact factor: 5.790

9.  Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

Authors:  Samuel L Aitken; Jeffrey J Tarrand; Lalitagauri M Deshpande; Frank P Tverdek; Anne L Jones; Samuel A Shelburne; Randall A Prince; Micah M Bhatti; Kenneth V I Rolston; Ronald N Jones; Mariana Castanheira; Roy F Chemaly
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079
View more
  5 in total

Review 1.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

2.  Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.

Authors:  Philippe Guerci; Hugo Bellut; Mokhtar Mokhtari; Julie Gaudefroy; Nicolas Mongardon; Claire Charpentier; Guillaume Louis; Parvine Tashk; Clément Dubost; Stanislas Ledochowski; Antoine Kimmoun; Thomas Godet; Julien Pottecher; Jean-Marc Lalot; Emmanuel Novy; David Hajage; Adrien Bouglé
Journal:  Crit Care       Date:  2019-11-21       Impact factor: 9.097

Review 3.  Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  Maximilian Christopeit; Martin Schmidt-Hieber; Rosanne Sprute; Oliver A Cornely; Georg Maschmeyer; Dieter Buchheidt; Marcus Hentrich; Meinolf Karthaus; Olaf Penack; Markus Ruhnke; Florian Weissinger
Journal:  Ann Hematol       Date:  2020-10-20       Impact factor: 3.673

Review 4.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

Review 5.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.